Ratings AroCell AB

Equities

AROC

SE0003883990

Delayed Nasdaq Stockholm Other stock markets 10:59:38 15/05/2024 BST			5-day change	1st Jan Change
0.395 ^SEK	-5.50%		-11.24%	-9.61%

05-03	AroCell AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-18	Swedish Diagnostics Company AroCell Secures US Patent	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
With regards to fundamentals, the enterprise value to sales ratio is at 0.91 for the current period. Therefore, the company is undervalued.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
AROCELL AB	-9.61%	8.9M	-
MODERNA, INC.	+29.03%	49.18B	B-
IQVIA HOLDINGS INC.	-0.10%	42.11B	B
LONZA GROUP AG	+49.11%	40.37B	A
CELLTRION, INC.	-5.26%	28.85B	C
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B	B
BIO-TECHNE CORPORATION	+9.06%	13.26B	B+
MEDPACE HOLDINGS, INC.	+30.01%	12.32B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes